RemovedRisk Factors
Additionally, artificial intelligence (“AI”) based software is increasingly being used in the biopharmaceutical industry. Use of AI based software may lead to the inadvertent release of confidential proprietary information, which may impact our ability to realize the benefit of our intellectual property.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RewordedRisk Factors
The aggregate amount of our consolidated indebtedness, net of debt discount, as of December 31, 2024 2025 was $1,505.8 $2,142.6 million, which includes $805.0 $209.6 million in aggregate principal amount of the 2027 Convertible Notes and $720.0 Notes, $470.0 million in aggregate principal of the 2028 Convertible Notes, $750.0 million in aggregate principal of the 2031 Convertible Notes and $750.0 million in aggregate principal of the 2032 Convertible Notes, net of unamortized debt discount of $7.5 $1.1 million, $5.6 million, $15.1 million and $11.7 million $15.2 million, for the 2027 Convertible Notes and Notes, 2028 Convertible Notes, 2031 Convertible Notes and 2032 Convertible Notes, respectively.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Public health crises such as pandemics or similar outbreaks could adversely impact our business and results of operations by, among other things, disrupting the development of our and our partnered product candidates and commercialization of our and our partnered approved products, causing disruptions in the operations of our third-party contract manufacturing organizations upon whom we rely for the production and supply of our proprietary products, including Hylenex and the bulk rHuPH20 we supply to our partners, and causing other disruptions to our operations.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in May 2022, we acquired Antares (in May 2022), Elektrofi (in November 2025), and Surf Bio (in December 2025), as a means to grow and diversify the sources of our revenues.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
The 2022 Credit Agreement also includes financial covenants requiring us to maintain, measured as of the end of each fiscal quarter, a maximum consolidated net leverage ratio of 4.75 4.50 to 1.00 initially, which declines to 4.00 to 1.00 over the term of the loan facility, initially and a minimum consolidated interest coverage ratio of 3.00 to 1.00.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, the approval of the HYQVIA Biologics License Application was delayed by the FDA until we and our partner provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
In order to augment and extend our revenue, we acquired Antares in (in May 2022 2022), Elektrofi (in November 2025), and Surf Bio (in December 2025) and we may decide to acquire additional businesses, products and technologies or pursue other corporate transactions and make investments which we believe are important to the future of our business.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Taken together, these decisions could make it more difficult and costly for us to obtain, license and enforce our patents.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Several other Legislative proposals have been introduced that, if enacted and implemented, could affect access to and sales of our and revenue from our partners’ products, allow the federal government to engage in price negotiations on certain drugs, and allow importation of prescription medication from Canada or other countries.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
There can be no assurance that our investment in Antares these acquisitions or any such future investment of resources in new technologies will ultimately result in additional approved proprietary or partnered products or commercial success of new therapeutic applications of our technology.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in August 2022, “The The Inflation Reduction Act of 2022” 2022 (the “IRA”) was enacted which will, among other things, allow and require the federal government to negotiate prices for some drugs covered under Medicare Part B and Part D, require drug companies to pay rebates to Medicare if prices rise faster than inflation for drugs used by Medicare beneficiaries and cap out-of-pocket spending for individuals enrolled in Medicare Part D.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
The federal administration and/or agencies, such as the Centers for Medicare & Medicaid Services, or CMS, Services (“CMS”), have announced a number of demonstration projects, recommendations and proposals to implement various elements described in the drug pricing blueprint.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
Through our recent acquisition of Elektrofi, Inc. (“Elektrofi”), subsequently renamed Halozyme Hypercon, Inc. (“Hypercon”), we have Hypercon collaboration and license agreements with Janssen, Lilly, and argenx. In addition to receiving upfront license fees from our Hypercon collaborations, we are entitled to receive event and sales-based milestone payments and royalties from commercial sales for approved partner products go-formulated with Hypercon.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In December 2025, Roche nominated a new undisclosed non-exclusive target to be studied using ENHANZE.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In April 2025, Roche received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending an update to the European Union (“EU”) label for Phesgo for human epidermal growth factor receptor 2-positive breast cancer. Administration of Phesgo outside of a clinical setting (such as in a person’s home) by a healthcare professional will be possible, once safely established in a clinical setting.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In the fourth quarter of 2025, the ongoing argenx ARGX-121 Phase 1 program was expanded to include an SC-arm evaluating ARGX-121 with ENHANZE in healthy adults.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In June 2025, argenx announced European Commission approval of VYVGART SC with ENHANZE for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy after prior treatment with corticosteroids or immunoglobulins. VYVGART SC injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In December 2025, Janssen received approval from the National Medical Products Administration in China for RYBREVANT FASPRO for the first-line treatment of adult patients with advanced non-small cell lung cancer.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In December 2025, we and Takeda entered into a new global collaboration and exclusive license agreement which provides Takeda with access to ENHANZE for use with vedolizumab, marketed globally as ENTYVIO®, for the treatment of adults with moderately to severely active Crohns’ disease or ulcerative colitis, which are the two main forms of inflammatory bowel disease.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In March 2025, Takeda announced Health Canada expanded the marketing authorization for HYQVIA to include chronic inflammatory demyelinating polyneuropathy as a maintenance therapy after stabilization with intravenous immunoglobulin to prevent relapse of neuromuscular disability and impairment in adults.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In May 2025, BMS received European Commission approval of Opdivo SC, the SC formulation of Opdivo (nivolumab) developed with ENHANZE, for use across multiple adult solid tumors.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In March 2025, Acumen announced top-line results from a Phase 1 study of sabirnetug (ACU193) with ENHANZE comparing the pharmacokinetics between SC and IV administrations in healthy volunteers that demonstrated weekly SC administration of sabirnetug was well-tolerated with systematic exposure supporting further clinical development.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In December 2025, we entered into a commercial license and supply agreement with Viatris under which we license and supply an auto-injector product for self-administered SC selatogrel for the treatment of acute myocardial infarction in adult patients.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•In November 2025, we and Merus entered into a non-exclusive global collaboration and license agreement that provides Merus access to ENHANZE technology for a single target. Merus intends to explore development and potential commercialization of SC administration of petosemtamab, an epidermal growth factor receptor and leucine-rich repeat-containing G-protein coupled receptor 5 bispecific antibody, for the treatment of head and neck cancer.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RemovedMD&A
•In September 2024, Roche announced the U.S. Food and Drug Administration (“FDA”) approved OCREVUS ZUNOVO with ENHANZE as a twice a year ten-minute SC injection for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis, and in July 2024 and June 2024, Roche announced the Medicines and Healthcare products Regulatory Agency and European Commission granted marketing authorization in Great Britain and the European Union (“EU”), respectively, for Ocrevus (ocrelizumab) SC for the same indications marking our eight approved partner product with ENHANZE.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In September 2024, Roche announced the FDA approved TECENTRIQ HYBREZA with ENHANZE for all approved adult indications of IV TECENTRIQ and was made available to patients, resulting in a $12.0 million milestone payment.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In April 2024, Roche’s MabThera SC was approved by the China National Medical Products Administration to treat diffuse large B-cell lymphoma.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In January 2024, Roche received European Commission marketing authorization for Tecentriq SC for all approved indications of Tecentriq IV for multiple cancer types.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In November 2024, Zai Lab Limited (argenx commercial partner for China) announced the National Medical Products Administration approval of VYVGART Hytrulo for the treatment of patients with chronic inflammatory demyelinating polyneuropathy.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In October 2024, argenx initiated two studies evaluating VYVGART Hytrulo with ENHANZE, a Phase 3 study for adult patients with ocular myasthenia gravis and a Phase 2 study for kidney transplant recipients with antibody mediated rejection.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In September 2024, argenx expanded its global collaboration and license agreement nominating four additional targets that provides them exclusive access to our ENHANZE drug delivery technology for a total of six targets. Under the terms of the expanded exclusive agreement, we received upfront payments of $7.5 million per target nomination for a total of $30.0 million. argenx is obligated to make future milestone payments of up to $85.0 million per new nominated target, subject to achievements of specified development, regulatory and sales-based milestones. We are also entitled to receive royalties on net sales of commercialized products with our ENHANZE technology.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In July 2024, argenx announced the National Medical Products Administration approved the Biologics License Application of efgartigimod SC for generalized myasthenia gravis in China.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In the first quarter of 2024, argenx initiated two registrational studies evaluating efgartigimod with ENHANZE administered by pre-filled syringe in subjects with thyroid eye disease.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In August 2024, the FDA designated Janssen’s Biologics License Application priority review status for amivantamab SC in combination with LAZCLUZE for currently approved or submitted indication of IV in certain patients with epidermal growth factor receptor-mutated non-small cell lung cancer. In December 2024, Janssen announced the FDA issued a Complete Response Letter for the Biologics License Application related to observations as part of a standard pre-approval inspection at a manufacturing facility. Janssen has indicated they are working closely with the FDA to bring SC amivantamab to patients as quickly as possible.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In September 2024, ViiV expanded its global collaboration and license agreement providing ViiV the ability to exclusively access our ENHANZE drug delivery technology for one additional undisclosed target.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•In June 2024, Takeda announced that Health Canada approved HYQVIA as a replacement therapy for Primary Immunodeficiency and secondary immunodeficiencies in pediatric patients two years of age and older.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RewordedMD&A
The decrease in net cash used in financing activities was primarily due to $1.5 billion cash received from the 2031 and 2032 Convertible Notes offering, partially offset by cash paid on the induced conversion of the 2027 and 2028 Convertible Notes of $1.0 billion, including a decrease premium and inducement expense, an increase in share repurchase of common stock by $152.4 of $92.4 million and $13.5 million in cash paid on the conversion of our 2024 Convertible Notes in the prior year, partially offset by an increase a decrease in net proceeds from the issuance of common stock under our equity incentive plan.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in product sales, net was primarily due to increased sales of bulk rHuPH20 driven by partner demand as well as contributions from our proprietary products product XYOSTED driven by continued market penetration, partially offset by lower sales of bulk rHuPH20 driven by the lower cost of the product which is passed on to partners and the timing of partner demand, and device partnered products driven by the timing of partner demand. product sales.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, Increase / (Decrease) 2025 2024 2023 Dollar Percentage Upfront license and target nomination fees $ 18,471 $ 27,000 $ 2,000 $ 25,000 1,250% (8,529) (32)% Event-based development milestones, and regulatory milestones and other fees 47,000 72,500 69,000 3,500 5 % (25,500) (35)% Sales-based milestones 70,000 30,000 — 30,000 100 % 40,000 133% Device licensing and development revenue 16,856 11,341 9,534 1,807 19 % 5,515 49% Total revenues under collaborative agreements $ 152,327 $ 140,841 $ 80,534 $ 60,307 75 % 11,486 8%
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
In May 2022, we entered into a credit agreement, which was subsequently amended (i) in August 2022 (the “Amendment”), “First Amendment”), (ii) in March 2023 (the “Second Amendment”) and (iii) in November 2025 (the “Third Amendment”) with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the credit agreement as amended by the First Amendment, the Second Amendment and the Third Amendment, the “2022 Credit Agreement”), evidencing a credit facility (the “2022 Facility”) that provides originally provided for (i) a $575 million revolving credit facility (the “Revolving Credit Facility”) and (ii) a $250 million term loan facility (the “Term Facility”).
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
We expect royalty revenue to grow further grow as a result of anticipated increasing partner product sales of DARZALEX SC SC, Phesgo and Phesgo, and sales of recently launched ENHANZE partner products, VYVGART Hytrulo, TECENTRIQ SC, OCREVUS SC and Opdivo Qvantig. the largest drivers of our royalty revenues.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, (in thousands) 2025 2024 2023 Change Net cash provided by operating activities $ 651,558 $ 479,064 $ 388,571 $ 90,493 172,494 Net cash used in investing activities (545,813) (262,723) (96,909) (165,814) (283,090) Net cash used in by financing activities (85,174) (218,861) (407,987) 189,126 133,687 Net decrease increase (decrease) in cash, cash equivalents and restricted cash $ 20,571 $ (2,520) $ (116,325) $ 113,805 23,091
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in royalties was primarily driven by continued sales uptake of ENHANZE partner products that have launched since 2020, predominantly VYVGART Hytrulo by argenx, DARZALEX SC by Janssen and Phesgo by Roche in all geographies, and the prior year launch of Vyvgart Hytrulo by argenx. geographies.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in research and development expense was primarily due to the acquisition of Elektrofi and Surf Bio, partially offset by lower compensation expense driven by resource optimization, labor allocation initiatives, and timing of planned investments in ENHANZE related to the development of our new high-yield rHuPH20 manufacturing processes. process.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in cost of sales was primarily due to lower bulk rHuPH20 an increase in product sales and device sales, partially offset by higher proprietary product sales. labor allocation initiatives.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in net cash used in investing activities was primarily due to $1.0 billion spent to acquire Elektrofi and Surf Bio, partially offset by an increase in net purchases sales and maturities of marketable securities, partially offset by securities and a decrease in capital spend for property and equipment.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
The 2028 2031 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
(2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new